Could a common asthma drug protect preemie lungs?

NCT ID NCT07101640

Recruiting now Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 4 times

Summary

This study tests montelukast, an asthma drug, in 28 premature infants at high risk for bronchopulmonary dysplasia (BPD), a serious lung condition. Researchers want to see if the drug is safe and how it moves through the body. The infants receive montelukast or a placebo daily for up to 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: montelukast
What this could lead to: If it works, this could point toward a treatment to reduce lung damage in premature infants with bronchopulmonary dysplasia.
What could go wrong: This is an early phase 1/2 trial with only 28 infants, so it is too small to prove effectiveness. The optimal dose is still unknown, and the drug may not provide clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA (BPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchopulmonary dysplasia Critical Illness Premature Birth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHOPULMONARY DYSPLASIA (BPD) CRITICAL ILLNESS PREMATURE BIRTHS

Contacts and locations

Locations

Arkansas Children's Hospital
RECRUITING

Little Rock, Arkansas, 72202, United States
East Carolina University
RECRUITING

Greenville, North Carolina, 27858, United States
University Medical Center of Southern Nevada
RECRUITING

Las Vegas, Nevada, 89102, United States
University of Massachusetts
RECRUITING

Amherst, Massachusetts, 01003, United States
University of North Carolina (UNC)
RECRUITING

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.